|Cancer Stem Cell News 9.01 January 15, 2020|
Arf1 ablation in cancer cells induced mitochondrial defects, endoplasmic-reticulum stress, and the release of damage-associated molecular patterns, which recruited and activated dendritic cells at tumor sites. [Nat Commun]
Investigators used a skin carcinogenesis model, which showed early tumor initiation in Sfrp1 knockout mice and increased tumorigenic potential of Sfrp1 knockout cancer stem cells. [Stem Cell Reports]
Researchers studied how ionizing radiation affected the expression of miRNAs related to stemness in different molecular breast cancer subtypes. [Mol Oncol]
The authors designed an oligodeoxynucleotide for targeting of signal transducer and activator of transcription 3 (STAT3) transcription factor which was involved in stemness, and constitutively activated in triple-negative breast cancer. [J Cell Physiol]
Aryl hydrocarbon receptor-deficient tumors and cancer-propagating cells grown in vitro showed elevated activation of the TGFβ mediator, SMAD3. [Sci Rep]
Through screening the genes involved in glycolysis, scientists identified the downstream targets of collagen XVII that were involved in metabolic reprogramming of lung cancer stem cells. [J Biomed Sci]
Investigators evaluated the proteome and miRNome content of extracellular microvesicles released by highly-aggressive stem-like medulloblastoma cells overexpressing the pluripotent factor OCT4A. These cells displayed enhanced tumor initiating capability and resistance to chemotherapeutic agents. [Brain Res]
The authors showed that L1CAM+ cells in human colorectal cancer have metastasis-initiating capacity, and defined their relationship to tissue regeneration. [Nat Cancer]
The authors provide a synopsis of the drug repurposing methodologies that have been used in pediatric brain tumors, and they argue how this selective compilation of approaches, with a focus on CSC targeting, could elevate drug repurposing to the next level. [Cancer Metastasis Rev]
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
Adaptive Biotechnologies Corporation announced a multi-year, global diagnostic agreement with Genentech to utilize Adaptive’s next-generation sequencing-based clonoSEQ® Assay to assess minimal residual disease status in response to venetoclax in the registrational Phase III CRISTALLO study for the treatment of newly diagnosed people with chronic lymphocytic leukemia (CLL) plus additional future venetoclax studies in CLL. [Adaptive Biotechnologies Corporation]
Medigene AG published topline results from its completed open-label Phase I/II clinical trial of Medigene’s autologous dendritic cell (DC) vaccine in 20 patients with acute myeloid leukemia (AML). The study was conducted at the Oslo University Hospital, Norway. Data were collected shortly after completion of the clinical trial, after 24 months of vaccination and follow-up of all patients. [Medigene AG]
Florida is launching a statewide investigation into US research exploitation after four University of Florida faculty members and six employees of Moffitt Cancer Center in Tampa failed to disclose ties to foreign programs, reports the Tampa Bay Times. [The Scientist]
For 20 years, the US government has urged companies, universities, and other institutions that conduct clinical trials to record their results in a federal database, so doctors and patients can see whether new treatments are safe and effective. [STAT News]
For several weeks the world has watched as India’s citizens – including academics and students – have taken to the streets. Tens of thousands have been gathering to read out the preamble to the Indian constitution, as a mark of protest against a discriminatory new citizenship law. [Nature News]
NEW 2nd Epigenetics Conference
Visit our events page to see a complete list of events in the community.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!
Comments or suggestions? Submit your feedback here.